These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36430448)

  • 1. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome.
    Lucarelli G; Rutigliano M; Loizzo D; di Meo NA; Lasorsa F; Mastropasqua M; Maiorano E; Bizzoca C; Vincenti L; Battaglia M; Ditonno P
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of MUC1 in Renal Cell Carcinoma.
    Milella M; Rutigliano M; Lasorsa F; Ferro M; Bianchi R; Fallara G; Crocetto F; Pandolfo SD; Barone B; d'Amati A; Spilotros M; Battaglia M; Ditonno P; Lucarelli G
    Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation.
    Lucarelli G; Netti GS; Rutigliano M; Lasorsa F; Loizzo D; Milella M; Schirinzi A; Fontana A; Di Serio F; Tamma R; Ribatti D; Battaglia M; Ranieri E; Ditonno P
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.
    Lucarelli G; Rutigliano M; Sanguedolce F; Galleggiante V; Giglio A; Cagiano S; Bufo P; Maiorano E; Ribatti D; Ranieri E; Gigante M; Gesualdo L; Ferro M; de Cobelli O; Buonerba C; Di Lorenzo G; De Placido S; Palazzo S; Bettocchi C; Ditonno P; Battaglia M
    Medicine (Baltimore); 2015 Nov; 94(46):e2117. PubMed ID: 26579829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.
    Aubert S; Fauquette V; Hémon B; Lepoivre R; Briez N; Bernard D; Van Seuningen I; Leroy X; Perrais M
    Cancer Res; 2009 Jul; 69(14):5707-15. PubMed ID: 19549898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma.
    Lucarelli G; Rutigliano M; Ferro M; Giglio A; Intini A; Triggiano F; Palazzo S; Gigante M; Castellano G; Ranieri E; Buonerba C; Terracciano D; Sanguedolce F; Napoli A; Maiorano E; Morelli F; Ditonno P; Battaglia M
    Urol Oncol; 2017 Jul; 35(7):461.e15-461.e27. PubMed ID: 28359744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression.
    Hu J; Wang SG; Hou Y; Chen Z; Liu L; Li R; Li N; Zhou L; Yang Y; Wang L; Wang L; Yang X; Lei Y; Deng C; Li Y; Deng Z; Ding Y; Kuang Y; Yao Z; Xun Y; Li F; Li H; Hu J; Liu Z; Wang T; Hao Y; Jiao X; Guan W; Tao Z; Ren S; Chen K
    Nat Genet; 2024 Mar; 56(3):442-457. PubMed ID: 38361033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
    Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
    Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma.
    Lucarelli G; Ferro M; Loizzo D; Bianchi C; Terracciano D; Cantiello F; Bell LN; Battaglia S; Porta C; Gernone A; Perego RA; Maiorano E; Cobelli O; Castellano G; Vincenti L; Ditonno P; Battaglia M
    Metabolites; 2020 Dec; 10(12):. PubMed ID: 33322148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.
    Lucarelli G; Rutigliano M; Sallustio F; Ribatti D; Giglio A; Lepore Signorile M; Grossi V; Sanese P; Napoli A; Maiorano E; Bianchi C; Perego RA; Ferro M; Ranieri E; Serino G; Bell LN; Ditonno P; Simone C; Battaglia M
    Aging (Albany NY); 2018 Dec; 10(12):3957-3985. PubMed ID: 30538212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma.
    Su H; Wang H; Shi G; Zhang H; Sun F; Ye D
    Eur J Surg Oncol; 2018 Jun; 44(6):840-846. PubMed ID: 29433989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma.
    de Carvalho PA; Bonatelli M; Cordeiro MD; Coelho RF; Reis S; Srougi M; Nahas WC; Pinheiro C; Leite KRM
    Carcinogenesis; 2021 Dec; 42(12):1420-1427. PubMed ID: 34668521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma.
    Xue S; Li QW; Che JP; Guo Y; Yang FQ; Zheng JH
    Int J Clin Exp Pathol; 2015; 8(4):3765-74. PubMed ID: 26097558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
    Peng Y; Greenland NY; Lang UE; Stohr BA
    Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Mucin-1 (CA15-3) Levels in Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 Mutations.
    Vylet'al P; Kidd K; Ainsworth HC; Springer D; Vrbacká A; Přistoupilová A; Hughey RP; Alper SL; Lennon N; Harrison S; Harden M; Robins V; Taylor A; Martin L; Howard K; Bitar I; Langefeld CD; Barešová V; Hartmannová H; Hodaňová K; Zima T; Živná M; Kmoch S; Bleyer AJ
    Am J Nephrol; 2021; 52(5):378-387. PubMed ID: 34098564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MUCINs expression signature impacts overall survival in patients with clear cell renal cell carcinoma.
    Meng H; Jiang X; Huang H; Shen N; Guo C; Yu C; Yin G; Wang Y
    Cancer Med; 2021 Sep; 10(17):5823-5838. PubMed ID: 34327857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.